Agilon Health price target raised to $22 from $6.25 at BofA

BofA analyst Craig Jones raised the firm’s price target on Agilon Health (AGL) to $22 from $6.25 and keeps an Underperform rating on the shares. The firm revised estimates to reflect increased 2026 guidance and shifted to a peer multiple on positive free cash flow guidance as cash concerns become less immediate. However, it reiterates an Underperform rating as it remains cautious on 2026 MLR improvements and awaits validation on 2026 trend with the Q2 results.